MilliporeSigma Elevates Its BioContinuum Platform Strategy To Deliver ‘ContiGuous' Bioprocessing

• Launch taking place at the International Pharmaceutical Expo (INTERPHEX) in New York
• “ContiGuous”processing will deliver seamless physical and digital integration of BioContinuum Platform building blocks
• BioContinuum Buffer Delivery Platform is first-of-its-kind integrated solution for streamlined buffer management

MilliporeSigma recently unveiled its BioContinuum Buffer Delivery Platform, a new building block in the BioContinuum Platform for next-generation bioprocessing, at INTERPHEX in New York City. The BioContinuum Buffer Delivery Platform is part of MilliporeSigma’s BioContinuum Platform to deliver “contiGuous” bioprocessing.

“MilliporeSigma’s vision goes beyond continuous manufacturing and will deliver contiGuous bioprocessing — a seamless confluence of digital and intensified bioprocessing building blocks,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma. “Our BioContinuum Buffer Delivery Platform is a perfect example of the high degree of connectivity that contiGuous biomanufacturing can achieve.”

The BioContinuum Buffer Delivery Platform is an integrated solution for more efficient buffer delivery and is tailored to provide the highest level of accuracy and precision in buffer preparation and management. Its launch is timely, as industry adoption of liquid buffers is expected to expand from seven to 56 percent, according to MilliporeSigma’s internal market research.

MilliporeSigma has obtained certain exclusive rights to sell the buffer dilution system developed by LEWA-Nikkiso America Inc (now a part of YMC Co., Ltd.) for customers involved in the development or production of diagnostics and biopharmaceuticals. This buffer dilution system offers the highest accuracy available for dilution of highly concentrated buffer, and MilliporeSigma is the only supplier providing such an integrated offering. MilliporeSigma’s BioContinuum Buffer Delivery Platform supplies process buffers at a fraction of the resources and facility space, resulting in a more streamlined buffer suite and a more efficient manufacturing process.

The configurable platform is comprised of four components: a selection of distinct buffer concentrates, reliably delivered in Mobius Select single-use assemblies and an automated, highly accurate and precise buffer dilution system with tailored system services.

ContiGuous manufacturing goes beyond just connecting the individual unit operations — it will include the orchestration and management of all the processing steps (materials, production, testing and analytics) with an industry-leading streamlined and optimized approach.

MilliporeSigma also introduced Emprove Evolve, a new product line under the Emprove Program. Emprove Evolve provides a new area of regulatory support in risk assessment for critical raw materials, helping drug manufacturers meet developing regulatory requirements. The program contains a high level of product characterization and documentation, providing more control of the manufacturing process and allowing manufacturers to select the appropriate quality of raw materials for drug development.

MilliporeSigma experts will be available to discuss the company’s advanced technologies, applications and services that help biomanufacturers bring therapies to market, delivering them to patients faster and more cost-effectively than ever before, at booth #2841, April 2-4 at the Javits Center.

About The Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 20,000 employees and 60 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17B acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125B global life science industry.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany generated sales of €14.8 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information, visit www.emdgroup.com.